Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer

The absence of progesterone receptors may relate to the failure of progestin treatment. The use of progestin treatment for well-differentiated early endometrial carcinoma should be cautious and requires very careful clinical evaluation before and after treatment.